Ian Chan is leading his biotech company, Abpro, to the front lines of the global race to develop new antibody treatments against the increasing number of COVID-19 variants. With many vaccines’ effectiveness against COVID variants in question, these antibody treatments will be key in fighting the variants. Abpro is conducting a clinical trial for its drug, which is considered the most advanced COVID antibody treatment being developed behind those of Big Pharma giants Regeneron and Eli Lilly. Though the current vaccines in the market and those being developed give the body the blueprint for fighting the common COVID virus, antibody treatments are administered to find and kill the virus and its various strains. These treatments will be used for people who don’t respond to the vaccines and might appeal to vaccine non-adopters. Recent preclinical data published in Nature Communications show Abpro’s drug binds to various COVID variants with high effectiveness, and it may even be effective in people who are infected with strains from the U.K. and South Africa, as well as new strains that have recently appeared in Boston and in New York.
See more notes:
Class of 1995